Aussie neurologists to lead stem cell trial for Parkinson’s

Melbourne neurologists have been chosen to lead a world-first trial using human parthenogenetic stem cells-derived neural stem cells (ISC-hpNSC) in patients with moderate to severe form of Parkinson’s disease.

The trial will be held by the Royal Melbourne Hospital after the California-based International Stem Cell Corporation successfully received TGA approval for the therapy.